Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Operations (2019 - 2025)

BridgeBio Pharma's Cash from Operations history spans 7 years, with the latest figure at 56420000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 71.11% year-over-year to 56420000.0; the TTM value through Dec 2025 reached 445910000.0, up 14.37%, while the annual FY2025 figure was 445910000.0, 14.37% up from the prior year.
  • Cash from Operations for Q4 2025 was 56420000.0 at BridgeBio Pharma, up from 109574000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 74703000.0 in Q2 2024 and bottomed at 219537000.0 in Q1 2024.
  • The 5-year median for Cash from Operations is 129357000.0 (2021), against an average of 120589200.0.
  • The largest annual shift saw Cash from Operations tumbled 272.22% in 2023 before it surged 165.9% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 133895000.0 in 2021, then skyrocketed by 30.36% to 93243000.0 in 2022, then tumbled by 33.86% to 124819000.0 in 2023, then tumbled by 56.49% to 195326000.0 in 2024, then surged by 71.11% to 56420000.0 in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Cash from Operations are 56420000.0 (Q4 2025), 109574000.0 (Q3 2025), and 80681000.0 (Q2 2025).